Clinical Trials Directory

Trials / Terminated

TerminatedNCT03499678

Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA

Clinical Trials on Detection of Lung Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells

Status
Terminated
Phase
Study type
Observational
Enrollment
81 (actual)
Sponsor
HKGepitherapeutics · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

A central challenge in the fight against lung cancers is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive imaging techniques for earlier detection of breast and lung cancers, these techniques are limited by the size of lesion that could be detected. Alternatively, several blood proteomic biomarkers have been proposed but none offer as of yet sufficient predictive power. Consequently, effective non-invasive tools as prognostic indicators and biomarkers of lung cancer is urgently needed. The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in lung cancer patients.

Conditions

Timeline

Start date
2018-07-01
Primary completion
2019-07-19
Completion
2019-07-19
First posted
2018-04-17
Last updated
2023-12-22

Locations

1 site across 1 country: Kazakhstan

Source: ClinicalTrials.gov record NCT03499678. Inclusion in this directory is not an endorsement.